E3 Ubiquitin Ligases in MASH ‐Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities
Liver International · 2026-10 · 46 (10)
DOI: 10.1111/liv.70850 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 28.08.2026. Verfasst von Ah-Reum Oh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Liver Cirrhosis, Ubiquitin-Protein Ligases, Fatty Liver. Die Arbeit nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Inha University, National Research Foundation of Korea, Korea Basic Science Institute.
Abstract (Originalsprache)
Metabolic dysfunction‐associated steatohepatitis (MASH) is a major cause of progressive liver fibrosis and can ultimately lead to cirrhosis and hepatocellular carcinoma (HCC). MASH‐associated liver fibrosis develops through a complex interplay among lipotoxic hepatocyte injury, oxidative and endoplasmic reticulum stress, inflammatory macrophage activation, hepatic stellate cell (HSC) activation and excessive extracellular matrix (ECM) deposition. E3 ubiquitin ligases, which determine substrate specificity within the ubiquitin‐proteasome system, have emerged as important regulators of these processes. By controlling protein stability, signalling complex formation, inflammatory responses, cellular stress, autophagy, ferroptosis and intercellular communication, E3 ubiquitin ligases can influence both fibrosis progression and resolution. Because E3 ubiquitin ligases may exert pro‐fibrotic or anti‐fibrotic effects depending on the substrate, cell types, metabolic environment and disease stage, their therapeutic targeting requires disease‐ and cell type‐specific strategies. In this review, we summarize the roles of E3 ubiquitin ligases in MASH‐related liver fibrosis, with a particular focus on their functions in hepatocytes, HSCs, macrophages and other liver‐resident cells. We also discuss emerging therapeutic approaches, including direct modulation of E3 ubiquitin ligase, proteolysis‐targeting chimeras (PROTACs), molecular glues and cell type‐specific delivery platforms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, Republic of Korea.
- Research Center for Controlling Intercellular Communication (RCIC), College of Medicine, Inha University, Incheon, Republic of Korea.
- Program in Biomedical Science & Engineering, Inha University, Incheon, Republic of Korea.
- Department of Biological Sciences, Jeonbuk National University, Jeonju, Republic of Korea.
ORCID-Profile: Ah-Reum Oh, Young Du Choi, Sang Bae Lee, KyeongJin Kim
Förderung
- Inha University
- National Research Foundation of Korea
- Korea Basic Science Institute
Zitieren
APA
Oh, A. R., Jeong, Y., Jung, Y. H., Kim, Y. U., Gi, H., Kim, D. W., Choi, Y. D., Lee, S. B., & Kim, K. (2026). E3 Ubiquitin Ligases in MASH ‐Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities. Liver International, 46(10). https://doi.org/10.1111/liv.70850
Vancouver
Oh AR, Jeong Y, Jung YH, Kim YU, Gi H, Kim DW, et al. E3 Ubiquitin Ligases in MASH ‐Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities. Liver International. 2026;46(10). doi:10.1111/liv.70850
BibTeX
@article{Oh2026,
author = {Oh, Ah-Reum and Jeong, Yelin and Jung, Young Hoon and Kim, Young Un and Gi, HyunJoon and Kim, Do-Wan and Choi, Young Du and Lee, Sang Bae and Kim, KyeongJin},
title = {E3 Ubiquitin Ligases in MASH ‐Associated Liver Fibrosis: Mechanisms and Therapeutic Opportunities},
journal = {Liver International},
year = {2026},
volume = {46},
number = {10},
doi = {10.1111/liv.70850}
}
EUVIMED